ONCAlert | Upfront Therapy for mRCC

Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma

Keith T. Flaherty, MD
Published Online: 4:50 PM, Tue June 4, 2019

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib (Braftovi) plus binimetinib (Mektovi) versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.